AKT1 and neoplasm: The mammalian target of rapamycin complex (mTOR) forms an essential effector of the PI3K/AKT pathway that provides positive feedback to the PI3K/AKT pathway and results in regular tumor growth, survival, motility, metabolism and eventually evading the effect of endocrine therapy [37,38].